Analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings per share of ($1.68) for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The highest EPS estimate is ($1.49) and the lowest is ($1.97). Ultragenyx Pharmaceutical reported earnings of ($1.74) per share in the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The business is expected to announce its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($6.72) per share for the current financial year, with EPS estimates ranging from ($7.42) to ($6.47). For the next financial year, analysts forecast that the firm will report earnings of ($5.21) per share, with EPS estimates ranging from ($7.36) to ($2.34). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The company had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. During the same period in the prior year, the company posted ($1.06) EPS. The firm’s quarterly revenue was up 88.8% compared to the same quarter last year.

Several equities analysts have recently issued reports on the stock. Piper Jaffray Companies set a $75.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, September 4th. ValuEngine cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Leerink Swann reiterated a “positive” rating and issued a $85.00 target price (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 4th. Barclays reissued a “buy” rating and set a $87.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Sunday, August 4th. Finally, Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an “overweight” rating on the stock in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $75.64.

In related news, EVP Karah Herdman Parschauer sold 1,226 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $61.50, for a total transaction of $75,399.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis bought 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average cost of $43.63 per share, with a total value of $218,150.00. Following the acquisition, the chief executive officer now owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The disclosure for this purchase can be found here. Insiders own 7.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of RARE. First Mercantile Trust Co. raised its stake in shares of Ultragenyx Pharmaceutical by 16.9% during the 2nd quarter. First Mercantile Trust Co. now owns 1,151 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Ultragenyx Pharmaceutical by 6.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 212 shares during the period. United Services Automobile Association grew its holdings in Ultragenyx Pharmaceutical by 0.7% during the second quarter. United Services Automobile Association now owns 31,483 shares of the biopharmaceutical company’s stock worth $1,999,000 after acquiring an additional 215 shares during the period. Smith Asset Management Group LP raised its position in Ultragenyx Pharmaceutical by 22.6% during the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 310 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Ultragenyx Pharmaceutical by 19.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 379 shares in the last quarter.

NASDAQ RARE traded up $1.88 during trading on Friday, hitting $45.01. The company’s stock had a trading volume of 1,933,591 shares, compared to its average volume of 542,595. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The company has a market cap of $2.60 billion, a PE ratio of -6.09 and a beta of 2.13. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.32 and a quick ratio of 9.14. The business’s 50 day simple moving average is $55.85 and its 200-day simple moving average is $61.69.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.